Therapeutic effectiveness of tocilizumab in the treatment of cytokine release syndrome in patients with COVID-19
Keywords:
Key words, COVID-19, coronavirus, SARS-CoV 2, tocilizumabAbstract
Introduction: tocilizumab, was approved in 2017 by the Food and Drugs Administration for the treatment of cytokine release syndrome, therefore it has been used in the treatment of severe patients due to SARS-CoV2. Objective: to describe the effectiveness of tocilizumab in the treatment of cytokine release syndrome in patients with COVID-19. Method: a review was carried out in the period from June 1 to August 30, 2020 for which the search strategy "coronavirus" was used. "COVID-19" OR "SARS-CoV2" AND "tocilizumab" in databases such as Pubmed, The Cochrane Library, Medline, LILACS. A total of 25 bibliographic references were selected. Development: the use of tocilizumab is associated with an improvement in both clinical, imaging and laboratory findings in patients with COVID-19 who develop cytokine release syndrome. Conclusions:many patients with COVID-19 have received concomitant treatment with antibiotics, antivirals and hydroxychloroquine prior to the administration of tocilizumab, so more research is needed to determine the effectiveness of tocilizumab without other concomitant therapy.
References
1. Zhang S, Li L, Shen A, Yongwu C, Zhigang Q. Rational. Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clinical Drug Investigation.[Internet] 2020 [citado 10 jun 2020]; 56:33–39. Disponible en: https://doi.org/10.1007/s40261-020-00917-3.
2. Xu J, Cai L, Shen Y. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang Da Xue
XueBao (YiXueBan). [Internet]. 2020 [citado 25 agosto 2020]; 46:23–30. Disponible en: https://kns.cnki.net/kcms/detail/33.1248.R.20200222.1417.002.html.
3. Wang D, Hu B, Hu C. Clinical Characteristics of 138
Hospitalized Patients With 2019 Novel Coronavirus-Infected
Pneumonia in Wuhan, China. JAMA. 2019. [Internet] 2020 [citado 25 agosto 2020]; 72:30–39. Disponible en: https://doi.org/10.1001/jama.2020.1585.
4. Jing L, Li S, Liu J. Longitudinal characteristics of lymphocyte responses and cytokine profles in the peripheral blood
of SARS-CoV-2 infected patients. MedRxiv. [Internet] 2020 (citado 20 agosto 2020); 80:43–49. Disponible en: https://doi.org/10.1101/2020.02.16.20023671.
5. Mastroianni A, Grecoa S, Apuzzoa G, Salvatore De Santis,
Oriolo C, Zanolini A, et al. Subcutaneous tocilizumab treatment in patients with severe COVID-19 related cytokine release syndrome: An observational cohort study. E Clinical Medicine. [Internet]. 2020 [citado 10 jun 2020]; 24:105-115. Disponible en: https://doi.org/10.1016/j.eclinm.2020.100410.
6. Kewana T, Covuta F, Mohammed J, AlJaghbeer, Lori R, Gopalakrishna, et al. Tocilizumab for treatment of patients with severe COVID19: A retrospective cohort study. E Clinical Medicine. [Internet] 2020 [citado 10 jun 2020]; 65:38–49. Disponible en: https://doi.org/10.1016/j.eclinm.2020.100418
7. Toniati P, Piva S, Cattalini M. Tocilizumab for the treatment of severe COVID- 19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia. Autoimmun Rev. [Internet] 2020 [citado 25 agosto 2020]; 45:35–47. Disponible en: http://doi:10.1016/j.autrev.2020.102568.
8. Colaneri M, Bogliolo L, Valsecchi P. Tocilizumab for treatment of severe
COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms [Internet] 2020 [citado 25 agosto 2020]; 83:24–29. Disponible en: http://doi.org/10.3390/microorganisms8050695.
9. Capra R, Rossi ND, Mattioli F. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med [Internet] 2020 [citado 25 agosto 2020]; 73:34–47. Disponible en: http://doi.org/10.1016/j.ejim.2020.05.009
10. Xu X, Han M, Li T. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci [Internet] 2020 [citado 25 agosto 2020]; 117:10970–5. Disponible en: http://doi:10.1016/j.autrev.2020.102568.
11. Remy KE, Bracknridge SC, Francois B. Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Resp Med.[Internet] 2020 [citado 15 julio 2020]. In press. Disponible en: https://doi.org/10.1016/j.eclinm.2020.100410.
12. Le RQ, Li L, Yuan W. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome. Oncologist 2018 [citado 25 agosto 2020]; 23(8):943–947. Disponible en: https://doi.org/10.1634/theoncologist.20180028.
13. Cortegiani A,Ippolito M, Greco M,Granone V, Protti A, Gregoretti C, et al. Rationale and evidence on the use of tocilizumab inCOVID-19: a systematic review. Pulmonology. [citado 25 junio 2020]; 67: 40–47. Disponible en: https://doi.org/10.1016/j.pulmoe.2020.07.003
14. Campochiaro C, Della-Torrea E, Cavallia G, Giacomo De Luca,
Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a singlecentre retrospective cohort study. European Journal of Internal Medicine. [Internet] 2020 [citado 10 julio 2020]; 76: 43–49. Disponible en: https://doi.org/10.1016/j.ejim.2020.05.021.
15. De Rossia N, Scarpazzab C, Filippinia C,Cordioli C, Rasia S,
Mancinelli CR, et al. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. E Clinical Medicine. [Internet]. 2020 [citado 10 julio 2020]; 100459: 158-165. Disponible en: https://doi.org/10.1016/j.eclinm.2020.100459.
16. Zhang Y, Zhong Y, Pan L. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: are we already that far. Drug Discov Ther. [Internet]. 2020 [citado 20 julio 2020]; 14:100–102. Disponible en: http://doi.org/10.5582/ddt.2020.03006.
17. Zhang X, Song K, Tong F. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Bloodadvances. [citado 15 julio 2020]; 4: 7-15. Disponible en: http://doi.org/10.1182/bloodadvances.2020001907.
18. Alzgharia SK, Valerie S. Acuñab. Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review. Journal of Clinical Virology. [Internet] 2020 [citado 18 julio 2020]; 127: 104-120. Disponible en: https://doi.org/10.1016/j.jcv.2020.104380.
19. Xua X, Hanb M, Lia T, Sun W, Wanga D, Binqing F, et al. Effective treatment of severe COVID-19 patients with tocilizumab. PNAS.[Internet] 2020 [citado 10 jun 2020];117: 20-28. Disponible en: www.pnas.org/cgi/doi/10.1073/pnas.2005615117.
20. Xu Z. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. [Internet] 2020 [citado 10 julio 2020]; 8: 420–422. Disponible en: http://doi.org/10.1016/S2213-2600(20)30076-X
21. Jones SA, Scheller J, John SR. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. [Internet] 2011 [citado 10 julio 2020]; 121: 3375–3383. Disponible en: http://pubmed.ncbi.nlm.nih.gov/21881215
22. Gabay C. ADACTA Study Investigators, Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. Lancet. [Internet] 2013 [citado 10 julio 2020]; 381: 1541–1550. Disponible en: http://pubmed.ncbi.nlm.nih.gov/23515142
23. Zhang JW, Hu X, Jin PF. Cytokine storm induced by SARS-CoV-2
and the drug therapy. Zhongguo Yao Xue Za Zhi. [Internet] 2020 [citado 10 julio 2020]; 271: 1441–1450. Disponible en: https://kns.cnki.net/kcms/detail/11.2162.R.20200225.1052.002.html.
24. Zhang YL, Jiang CY. Cytokine storm in ARDS. Sheng Ming Ke
Xue. [Internet] 2015 [citado 10 julio 2020]; 5:554–557. Disponible en: http://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC7194613
25. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. [Internet] 2020 [citado 10 julio 2020]; 381:1674–1687. Disponible en: http://doi.org/10.1016/S0140-6736(20)31180-6.
2. Xu J, Cai L, Shen Y. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang Da Xue
XueBao (YiXueBan). [Internet]. 2020 [citado 25 agosto 2020]; 46:23–30. Disponible en: https://kns.cnki.net/kcms/detail/33.1248.R.20200222.1417.002.html.
3. Wang D, Hu B, Hu C. Clinical Characteristics of 138
Hospitalized Patients With 2019 Novel Coronavirus-Infected
Pneumonia in Wuhan, China. JAMA. 2019. [Internet] 2020 [citado 25 agosto 2020]; 72:30–39. Disponible en: https://doi.org/10.1001/jama.2020.1585.
4. Jing L, Li S, Liu J. Longitudinal characteristics of lymphocyte responses and cytokine profles in the peripheral blood
of SARS-CoV-2 infected patients. MedRxiv. [Internet] 2020 (citado 20 agosto 2020); 80:43–49. Disponible en: https://doi.org/10.1101/2020.02.16.20023671.
5. Mastroianni A, Grecoa S, Apuzzoa G, Salvatore De Santis,
Oriolo C, Zanolini A, et al. Subcutaneous tocilizumab treatment in patients with severe COVID-19 related cytokine release syndrome: An observational cohort study. E Clinical Medicine. [Internet]. 2020 [citado 10 jun 2020]; 24:105-115. Disponible en: https://doi.org/10.1016/j.eclinm.2020.100410.
6. Kewana T, Covuta F, Mohammed J, AlJaghbeer, Lori R, Gopalakrishna, et al. Tocilizumab for treatment of patients with severe COVID19: A retrospective cohort study. E Clinical Medicine. [Internet] 2020 [citado 10 jun 2020]; 65:38–49. Disponible en: https://doi.org/10.1016/j.eclinm.2020.100418
7. Toniati P, Piva S, Cattalini M. Tocilizumab for the treatment of severe COVID- 19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia. Autoimmun Rev. [Internet] 2020 [citado 25 agosto 2020]; 45:35–47. Disponible en: http://doi:10.1016/j.autrev.2020.102568.
8. Colaneri M, Bogliolo L, Valsecchi P. Tocilizumab for treatment of severe
COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms [Internet] 2020 [citado 25 agosto 2020]; 83:24–29. Disponible en: http://doi.org/10.3390/microorganisms8050695.
9. Capra R, Rossi ND, Mattioli F. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med [Internet] 2020 [citado 25 agosto 2020]; 73:34–47. Disponible en: http://doi.org/10.1016/j.ejim.2020.05.009
10. Xu X, Han M, Li T. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci [Internet] 2020 [citado 25 agosto 2020]; 117:10970–5. Disponible en: http://doi:10.1016/j.autrev.2020.102568.
11. Remy KE, Bracknridge SC, Francois B. Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Resp Med.[Internet] 2020 [citado 15 julio 2020]. In press. Disponible en: https://doi.org/10.1016/j.eclinm.2020.100410.
12. Le RQ, Li L, Yuan W. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome. Oncologist 2018 [citado 25 agosto 2020]; 23(8):943–947. Disponible en: https://doi.org/10.1634/theoncologist.20180028.
13. Cortegiani A,Ippolito M, Greco M,Granone V, Protti A, Gregoretti C, et al. Rationale and evidence on the use of tocilizumab inCOVID-19: a systematic review. Pulmonology. [citado 25 junio 2020]; 67: 40–47. Disponible en: https://doi.org/10.1016/j.pulmoe.2020.07.003
14. Campochiaro C, Della-Torrea E, Cavallia G, Giacomo De Luca,
Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a singlecentre retrospective cohort study. European Journal of Internal Medicine. [Internet] 2020 [citado 10 julio 2020]; 76: 43–49. Disponible en: https://doi.org/10.1016/j.ejim.2020.05.021.
15. De Rossia N, Scarpazzab C, Filippinia C,Cordioli C, Rasia S,
Mancinelli CR, et al. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. E Clinical Medicine. [Internet]. 2020 [citado 10 julio 2020]; 100459: 158-165. Disponible en: https://doi.org/10.1016/j.eclinm.2020.100459.
16. Zhang Y, Zhong Y, Pan L. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: are we already that far. Drug Discov Ther. [Internet]. 2020 [citado 20 julio 2020]; 14:100–102. Disponible en: http://doi.org/10.5582/ddt.2020.03006.
17. Zhang X, Song K, Tong F. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Bloodadvances. [citado 15 julio 2020]; 4: 7-15. Disponible en: http://doi.org/10.1182/bloodadvances.2020001907.
18. Alzgharia SK, Valerie S. Acuñab. Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review. Journal of Clinical Virology. [Internet] 2020 [citado 18 julio 2020]; 127: 104-120. Disponible en: https://doi.org/10.1016/j.jcv.2020.104380.
19. Xua X, Hanb M, Lia T, Sun W, Wanga D, Binqing F, et al. Effective treatment of severe COVID-19 patients with tocilizumab. PNAS.[Internet] 2020 [citado 10 jun 2020];117: 20-28. Disponible en: www.pnas.org/cgi/doi/10.1073/pnas.2005615117.
20. Xu Z. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. [Internet] 2020 [citado 10 julio 2020]; 8: 420–422. Disponible en: http://doi.org/10.1016/S2213-2600(20)30076-X
21. Jones SA, Scheller J, John SR. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. [Internet] 2011 [citado 10 julio 2020]; 121: 3375–3383. Disponible en: http://pubmed.ncbi.nlm.nih.gov/21881215
22. Gabay C. ADACTA Study Investigators, Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. Lancet. [Internet] 2013 [citado 10 julio 2020]; 381: 1541–1550. Disponible en: http://pubmed.ncbi.nlm.nih.gov/23515142
23. Zhang JW, Hu X, Jin PF. Cytokine storm induced by SARS-CoV-2
and the drug therapy. Zhongguo Yao Xue Za Zhi. [Internet] 2020 [citado 10 julio 2020]; 271: 1441–1450. Disponible en: https://kns.cnki.net/kcms/detail/11.2162.R.20200225.1052.002.html.
24. Zhang YL, Jiang CY. Cytokine storm in ARDS. Sheng Ming Ke
Xue. [Internet] 2015 [citado 10 julio 2020]; 5:554–557. Disponible en: http://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC7194613
25. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. [Internet] 2020 [citado 10 julio 2020]; 381:1674–1687. Disponible en: http://doi.org/10.1016/S0140-6736(20)31180-6.
Downloads
Published
2021-03-15
How to Cite
1.
Denis-Piedra DA, Jiménez Puentes M, Isla Alfonso D. Therapeutic effectiveness of tocilizumab in the treatment of cytokine release syndrome in patients with COVID-19. Rev 16 de abril [Internet]. 2021 Mar. 15 [cited 2024 Dec. 13];60(279):e1026. Available from: https://rev16deabril.sld.cu/index.php/16_04/article/view/1026
Issue
Section
Review Articles
License
Those authors who have publications with this journal, accept the following terms:
The authors will retain their copyright and guarantee the journal the right of first publication of your work, which will be under a Creative license Commons Attribution-NonCommercial-ShareAlike 4.0 International . (CC BY-NC-SA 4.0).
The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (eg:deposit it in an institutional telemat
